<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>POTASSIUM CHLORIDE IN DEXTROSE- potassium chloride and dextrose monohydrate injection, solution </strong><br>Baxter Healthcare Corporation<br></p></div>
<h1>Potassium Chloride in 5% Dextrose Injection, USP <br>in Plastic Container  <br>VIAFLEX Plus Container </h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_29d5ba9e-3967-46b7-a5d5-3c1081c1c9b4"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Potassium Chloride in 5% Dextrose Injection, USP is a sterile, nonpyrogenic solution for fluid and electrolyte replenishment and caloric supply in a single dose container for intravenous administration.  It contains no antimicrobial agents.  Composition, osmolarity, pH, ionic concentration and caloric content are shown in Table 1.</p>
<table width="553.95pt">
<col width="23%">
<col width="6%">
<col width="11%">
<col width="10%">
<col width="11%">
<col width="11%">
<col width="11%">
<col width="9%">
<col width="9%">
<tfoot><tr><td colspan="9" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Normal physiologic osmolarity range is approximately 280 to 310 mOsmol/L.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule" rowspan="3"><p class="First"><span class="Bold">Table 1</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="5"><p class="First">Size (mL)</p></td>
<td class="Botrule Lrule Rrule Toprule" colspan="2" rowspan="1"><p class="First">Composition (g/L)</p></td>
<td class="Lrule Rrule Toprule" colspan="2"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" rowspan="1"><p class="First">Ionic Concentration (mEq/L)</p></td>
<td class="Botrule Lrule Rrule Toprule" rowspan="5"><p class="First">Caloric Content (kcal/L)</p></td>
</tr>
<tr>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="3"><p class="First">**Dextrose Hydrous, USP</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="3"><p class="First">Potassium Chloride, USP<br>(KCl)</p></td>
<td align="center" rowspan="3"><p class="First"><a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>Osmolarity (mOsmol/L) <br>(calc.)</p></td>
<td align="center" rowspan="3"><p class="First">pH</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="3"><p class="First"><span class="Bold">Potassium</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="3"><p class="First">Chloride</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule"><p class="First">Potassium Chloride in <br>5% Dextrose Injection, USP</p></td></tr>
<tr><td class="Botrule Lrule Rrule"><p class="First">mEq Potassium</p></td></tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"><p class="First">20 mEq</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1000</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">50</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">293</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4.5<br>(3.5 to 6.5)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">20</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">20</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">170</p></td>
</tr>
</tbody>
</table>
<div class="Figure">
<a name="id630"></a><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=45de5402-5e61-4bbd-8bbc-5e3392c9920e&amp;name=image-01.jpg"><p class="MultiMediaCaption"></p>
</div>
<p></p>
<p>This VIAFLEX Plus plastic container is fabricated from a specially formulated polyvinyl chloride (PL 146 Plastic).  VIAFLEX Plus on the container indicates the presence of a drug additive in a drug vehicle.  The VIAFLEX Plus plastic container system utilizes the same container as the VIAFLEX plastic container system.  The amount of water that can permeate from inside the container into the overwrap is insufficient to affect the solution significantly.  Solutions in contact with the plastic container can leach out certain of its chemical components in very small amounts within the expiration period, e.g., di-2- ethylhexyl phthalate (DEHP), up to 5 parts per million.  However, the safety of the plastic has been confirmed in tests in animals according to USP biological tests for plastic containers as well as by tissue culture toxicity studies.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_db57981a-500f-4ff3-a0db-f47d638a74c8"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Potassium Chloride in 5% Dextrose Injection, USP is a source of water, electrolytes and calories.  It is capable of inducing <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> depending on the clinical condition of the patient.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_ecc94309-5c8d-4fd2-8d69-3c37b1089762"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Potassium Chloride in 5% Dextrose Injection, USP is indicated as a source of water, electrolytes, and calories.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_04a4ccbf-03f2-4a35-aecd-27bb024fc901"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Solutions containing dextrose may be contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> to corn or corn products.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_a59ef5b1-614f-463b-8226-72673c6abe11"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>/infusion reactions, including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> and <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span> may occur.  The infusion must be stopped immediately if signs or symptoms of suspected <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> develop.  Appropriate therapeutic counter measures must be instituted as clinically indicated.  Solutions containing dextrose should be used with caution in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> to corn or corn products.</p>
<p>Potassium Chloride in 5% Dextrose Injection, USP should be used with great care, if at all, in patients with <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, severe <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, and in conditions in which potassium retention is present.</p>
<p>Injections containing carbohydrates with low electrolyte concentration should not be administered simultaneously with blood through the same administration set because of the possibility of pseudoagglutination or <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span>.  The bag label for these injections bears the statement:  Do not administer simultaneously with blood.</p>
<p>The intravenous administration of Potassium Chloride in 5% Dextrose Injection, USP can cause fluid and/or solute overloading resulting in dilution of serum electrolyte concentrations, <span class="product-label-link" type="condition" conceptid="4266976" conceptname="Overhydration">overhydration</span>, congested states, or <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>.  The risk of dilutional states is inversely proportional to the electrolyte concentrations of the injection.  The risk of solute overload causing congested states with peripheral and <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span> is directly proportional to the electrolyte concentrations of the injection.</p>
<p>In patients with diminished renal function, administration of Potassium Chloride in 5% Dextrose Injection, USP may result in potassium retention.</p>
<p>In very low birth weight infants, excessive or rapid administration of dextrose injection may result in increased serum <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span> and possible <span class="product-label-link" type="condition" conceptid="376713" conceptname="Cerebral hemorrhage">intracerebral hemorrhage</span>.</p>
<p>Potassium salts should never be administered by IV push.<br><br>Monitor changes in fluid balance, electrolyte concentrations, and acid base balance during prolonged parenteral therapy or whenever the condition of the patient warrants such evaluation.</p>
<p>Due to the risk of pseudo-agglutination precipitated by its glucose content, potassium chloride and 5.0% w/v glucose must not be added to or administered simultaneously through the same tubing with citrate anticoagulated/preserved blood.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_fe1e9b36-0cd1-4e1a-8f90-ce5999b42052"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="ID_4a64f0fc-7ee5-490e-a6fc-633c40b221ad"></a><a name="section-6.1"></a><p></p>
<h2>General </h2>
<p class="First">Do not connect flexible plastic containers in series in order to avoid <span class="product-label-link" type="condition" conceptid="4156949" conceptname="Air embolism">air embolism</span> due to possible residual air contained in the primary container.<br>Such use could result in <span class="product-label-link" type="condition" conceptid="4156949" conceptname="Air embolism">air embolism</span> due to residual air being drawn from the primary container before administration of the fluid from the secondary container is completed.</p>
<p>Pressurizing intravenous solutions contained in flexible plastic containers to increase flow rates can result in <span class="product-label-link" type="condition" conceptid="4156949" conceptname="Air embolism">air embolism</span> if the residual air in the container is not fully evacuated prior to administration. </p>
<p>Use of a vented intravenous administration set with the vent in the open position could result in <span class="product-label-link" type="condition" conceptid="4156949" conceptname="Air embolism">air embolism</span>. Vented intravenous administration sets with the vent in the open position should not be used with flexible plastic containers.</p>
<p>Potassium Chloride in 5% Dextrose Injection, USP should be used with caution in patients with overt or <span class="product-label-link" type="condition" conceptid="44808385" conceptname="Pre-diabetes">subclinical diabetes</span> mellitus.</p>
<p>For patients receiving potassium supplement at greater than maintenance rates, frequent monitoring of serum potassium levels and serial EKGs are recommended.</p>
<p>The osmolarity of Potassium Chloride in 5% Dextrose Injection, USP ranges from 272 to 333 mOsmol/L (calc). Administration of hypertonic solutions may cause venous irritation, including <span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">phlebitis</span>. Hyperosmolar solutions should be administered with caution, if at all, to patients with hyperosmolar states.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_7bf79325-cf49-4d53-92f8-4d32c5297e90"></a><a name="section-6.2"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a62a5817-3486-4b7a-b3f1-d23fe67556b6"></a><a name="section-6.2.1"></a><p></p>
<h3>Pregnancy Category C </h3>
<p class="First">There are no adequate and well controlled studies with Potassium Chloride in 5% Dextrose Injection, USP and animal reproduction studies have not been conducted with this drug.  Therefore, it is not known whether Potassium Chloride in 5% Dextrose Injection, USP can cause fetal harm when administered to a pregnant woman.  Potassium Chloride in 5% Dextrose Injection, USP should be given during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="ID_038daf9a-659c-49c5-821f-05fe6c241ff4"></a><a name="section-6.3"></a><p></p>
<h2>Labor and Delivery </h2>
<p class="First">Intrapartum maternal intravenous infusion of glucose-containing solutions may produce maternal <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> with subsequent fetal <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> and fetal <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span>.  Fetal <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> can result in increased fetal insulin levels which may result in <span class="product-label-link" type="condition" conceptid="23034" conceptname="Neonatal hypoglycemia">neonatal hypoglycemia</span> following delivery. Consider the potential risks and benefits for each specific patient before administering Potassium Chloride in 5% Dextrose Injection, USP.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_d73f1e6f-2fca-4e67-bffa-4fcf9bdacc5f"></a><a name="section-6.4"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether this drug is present in human milk.  Because many drugs are present in human milk, caution should be exercised when Potassium Chloride in 5% Dextrose Injection, USP is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_035c0cb0-b8f5-4d73-bb66-c06d066d38d5"></a><a name="section-6.5"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">The use of Potassium Chloride in 5% Dextrose Injection, USP in pediatric patients is based on clinical practice. (See <a href="#i4i_dosage_admin_id_f440476a-6177-4ee6-a37e-dc780ffd70a5">DOSAGE AND ADMINISTRATION</a>) </p>
<p>Newborns – especially those born premature and with low birth weight - are at increased risk of developing hypo- or <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> and therefore need close monitoring during treatment with intravenous glucose solutions to ensure adequate glycemic control in order to avoid potential long term adverse effects. <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> in the newborn can cause prolonged <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> and <span class="product-label-link" type="condition" conceptid="4080670" conceptname="Brain damage">brain damage</span>. <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span> has been associated with <span class="product-label-link" type="condition" conceptid="443752" conceptname="Ventricular hemorrhage">intraventricular hemorrhage</span>, late onset bacterial and <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infection</span>, <span class="product-label-link" type="condition" conceptid="373766" conceptname="Retinopathy of prematurity">retinopathy of prematurity</span>, <span class="product-label-link" type="condition" conceptid="201957" conceptname="Necrotizing enterocolitis in fetus OR newborn">necrotizing enterocolitis</span>, <span class="product-label-link" type="condition" conceptid="4283942" conceptname="Bronchopulmonary dysplasia of newborn">bronchopulmonary dysplasia</span>, prolonged length of hospital stay, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_61185e92-d64f-4a09-9241-61bb2a7cf1ea"></a><a name="section-6.6"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Clinical studies of Potassium Chloride in 5% Dextrose Injection, USP did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.  Other reported clinical experience has not identified differences in responses between the elderly and younger patients.  In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
<p>This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>.  Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_a2679105-38d6-4d23-aa4d-92769e3b2409"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span>, including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> and <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>.</p>
<p>Reactions which may occur because of the solution or the technique of administration include febrile response, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> at the site of injection, <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">venous thrombosis</span> or <span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">phlebitis</span> extending from the site of injection, <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span>, and <span class="product-label-link" type="condition" conceptid="434004" conceptname="Hypervolemia">hypervolemia</span>.</p>
<p>If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures, and save the remainder of the fluid for examination if deemed necessary.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_f440476a-6177-4ee6-a37e-dc780ffd70a5"></a><a name="section-8"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">As directed by a physician.  Dosage is dependent upon the age, weight and clinical condition of the patient as well as laboratory determinations.</p>
<p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.  Use of a final filter is recommended during administration of all parenteral solutions, where possible.</p>
<p>Do not administer unless solution is clear and seal is intact.</p>
<p>All injections in VIAFLEX Plus plastic containers are intended for intravenous administration using sterile equipment.</p>
<p>The dosage selection and constant infusion rate of intravenous dextrose must be selected with caution in pediatric patients, particularly neonates and low birth weight infants, because of the increased risk of <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>/<span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>. Frequent monitoring of serum glucose concentrations is required when dextrose is prescribed to pediatric patients, particularly neonates and low birth weight infants.  The infusion rate and volume depends on the age, weight, clinical and metabolic conditions of the patient, concomitant therapy and should be determined by the consulting physician experienced in pediatric intravenous fluid therapy.</p>
<p>Additives may be incompatible. Complete information is not available.  Those additives known to be incompatible should not be used.  Consult with pharmacist, if available. If, in the informed judgment of the physician, it is deemed advisable to introduce additives, use aseptic technique.  Mix thoroughly when additives have been introduced. Do not store solutions containing additives.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_370948ed-8659-4566-ac2a-bd34e0f2039a"></a><a name="section-9"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Potassium Chloride in 5% Dextrose Injection, USP in VIAFLEX Plus plastic container is available as follows:</p>
<table width="100%">
<col width="16%">
<col width="18%">
<col width="25%">
<col width="41%">
<tbody class="Headless">
<tr class="First Toprule">
<td><p class="First"><span class="Bold">Code</span></p></td>
<td><p class="First"><span class="Bold">Size (mL)</span></p></td>
<td><p class="First"><span class="Bold">NDC</span></p></td>
<td><p class="First"><span class="Bold">Product Name</span></p></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="Botrule Last">
<td><p class="First">2B1134</p></td>
<td><p class="First">1000</p></td>
<td><p class="First">0338-0683-04</p></td>
<td><p class="First">20 mEq Potassium Chloride <br>in 5% Dextrose Injection, USP</p></td>
</tr>
</tbody>
</table>
<p>Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. It is recommended the product be stored at room temperature (25°C); brief exposure up to 40°C does not adversely affect the product.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b2395f9c-d882-48d6-9c93-5a717f16a87e"></a><a name="section-10"></a><p></p>
<h1>DIRECTIONS FOR USE OF VIAFLEX PLUS PLASTIC CONTAINER </h1>
<p class="First">For information on risk of <span class="product-label-link" type="condition" conceptid="4156949" conceptname="Air embolism">air embolism</span> – see <a href="#i4i_precautions_id_fe1e9b36-0cd1-4e1a-8f90-ce5999b42052">PRECAUTIONS</a>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5f29c16c-1270-466e-9048-8040c32f45d0"></a><a name="section-10.1"></a><p></p>
<h2>To Open </h2>
<p class="First">Tear overwrap down side at slit and remove solution container.  Visually inspect the container. If the outlet port protector is damaged, <span class="product-label-link" type="condition" conceptid="4071366" conceptname="Indifference">detached</span>, or not present, discard container as solution path <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">sterility</span> may be impaired. Some opacity of the plastic due to moisture absorption during the sterilization process may be observed.  This is normal and does not affect the solution quality or safety.  The opacity will diminish gradually.  Check for minute leaks by squeezing inner bag firmly.  If leaks are found, discard solution as <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">sterility</span> may be impaired.  If supplemental medication is desired, follow directions below.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_948bfcfd-e0cd-4c80-bdc3-939e3c2a6a57"></a><a name="section-10.2"></a><p></p>
<h2>Preparation for Administration </h2>
<dl>
<dt>1.</dt>
<dd>Suspend container from eyelet support. </dd>
<dt>2.</dt>
<dd>Remove protector from outlet port at bottom of container. </dd>
<dt>3.</dt>
<dd>Attach administration set. Refer to complete directions accompanying set. </dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_51613124-f518-454f-bfef-d45f1340c38a"></a><a name="section-10.3"></a><p></p>
<h2>To Add Medication </h2>
<p class="First"><span class="Bold">Warning:</span> Additives may be incompatible. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_48f8523d-8728-43dc-943b-6901b2e2514c"></a><a name="section-10.3.1"></a><p></p>
<h3>To add medication before solution administration </h3>
<dl>
<dt>1.</dt>
<dd>Prepare medication site. </dd>
<dt>2.</dt>
<dd>Using syringe with 19 to 22 gauge needle, puncture resealable medication port and inject. </dd>
<dt>3.</dt>
<dd>Mix solution and medication thoroughly.  For high density medication such as potassium chloride, squeeze ports while ports are upright and mix thoroughly.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3596f3dc-515d-443a-a850-dc64b4f2f847"></a><a name="section-10.3.2"></a><p></p>
<h3><span class="Bold">To add medication during solution administration </span></h3>
<dl>
<dt>1.</dt>
<dd>Close clamp on the set. </dd>
<dt>2.</dt>
<dd>Prepare medication site. </dd>
<dt>3.</dt>
<dd>Using syringe with 19 to 22 gauge needle, puncture resealable medication port and inject. </dd>
<dt>4.</dt>
<dd>Remove container from IV pole and/or turn to an upright position. </dd>
<dt>5.</dt>
<dd>Evacuate both ports by squeezing them while container is in the upright position. </dd>
<dt>6.</dt>
<dd>Mix solution and medication thoroughly. </dd>
<dt>7.</dt>
<dd>Return container to in use position and continue administration.</dd>
</dl>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_426f9195-279a-4cd5-9b18-eb3c0c6b0c3c"></a><a name="section-11"></a><p></p>
<p class="First"><span class="Bold">Baxter Healthcare Corporation</span><br>Deerfield, IL 60015 USA</p>
<p>Printed in USA </p>
<p>07-19-74-596</p>
<p>Rev. March 2015</p>
<p>Baxter, PL 146, and Viaflex are trademarks of Baxter International Inc.</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_1e5df2df-ad54-4402-b83c-dbf2f5f8b467"></a><a name="section-12"></a><p></p>
<h1>PACKAGE LABELING - PRINCIPLE DISPLAY PANEL</h1>
<div class="Figure">
<a name="id856"></a><img alt="Potassium Chloride in Dextrose Representative Carton Label 0338-0683-04" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=45de5402-5e61-4bbd-8bbc-5e3392c9920e&amp;name=image-02.jpg"><p class="MultiMediaCaption">Carton Label</p>
</div>
<p class="First">2B1134X 14-1000 ML </p>
<p>VIAFLEX® PLUS CONTAINER </p>
<p>20 MEQ POTASSIUM CHLORIDE IN </p>
<p>5% DEXTROSE INJ USP </p>
<p>EXP <br>XXXXX </p>
<p>SECONDARY BAR CODE <br>(17) YYMM00 (10) XXXXX </p>
<p>LOT <br>XXXXX </p>
<p>PRIMARY BAR CODE <br>(01) 50303380683043 </p>
<div class="Figure">
<a name="id870"></a><img alt="Potassium Chloride in Dextrose Representative Container Label NDC 0338-0683-04" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=45de5402-5e61-4bbd-8bbc-5e3392c9920e&amp;name=image-03.jpg"><p class="MultiMediaCaption">Container Label </p>
</div>
<p>Container Label </p>
<p><span class="Bold">2B1134</span><br><span class="Bold">NDC 0338-0683-04</span><br><span class="Bold">DIN 00438049</span></p>
<p><span class="Bold">20 mEq</span><br><span class="Bold">Potassium Chloride</span><br><span class="Bold">(20 mEq/L)</span><br><span class="Bold">Potassium Chloride in</span><br><span class="Bold">5% Dextrose Injection USP</span></p>
<p><span class="Bold">1000 mL</span></p>
<p>EACH 100 mL CONTAINS 5 g DEXTROSE HYDROUS USP <br>150 mg POTASSIUM CHLORIDE USP pH 4.5 (3.5 TO 6.5) <br>mEq/L POTASSIUM 20 CHLORIDE 20 OSMOLARITY 293 <br>mOsmol/L (CALC) STERILE NONPYROGENIC SINGLE DOSE <br>CONTAINER ADDITIVES MAY BE INCOMPATIBLE CONSULT WITH <br>PHARMACIST IF AVAILABLE WHEN INTRODUCING ADDITIVES USE <br>ASEPTIC TECHNIQUE MIX THOROUGHLY DO NOT STORE <br>DOSAGE INTRAVENOUSLY AS DIRECTED BY A PHYSICIAN SEE <br>DIRECTIONS CAUTIONS SQUEEZE AND INSPECT INNER BAG <br>WHICH MAINTAINS PRODUCT <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">STERILITY</span> DISCARD IF LEAKS ARE <br>FOUND MUST NOT BE USED IN SERIES CONNECTIONS DO NOT <br>ADMINISTER SIMULTANEOUSLY WITH BLOOD DO NOT USE <br>UNLESS SOLUTION IS CLEAR <span class="Bold">RX ONLY</span> STORE UNIT IN <br>MOISTURE BARRIER OVERWRAP AT ROOM TEMPERATURE <br>(25°C/77°F) UNTIL READY TO USE AVOID EXCESSIVE HEAT <br>SEE INSERT <br>VIAFLEX PLUS CONTAINER PL 146 PLASTIC <br>BAXTER VIAFLEX AND PL 146 ARE TRADEMARKS OF <br>BAXTER INTERNATIONAL INC <br>FOR PRODUCT INFORMATION 1-800-933-0303</p>
<p><span class="Bold"><span class="Italics">Baxter Logo</span></span></p>
<p><span class="Bold">BAXTER HEALTHCARE CORPORATION</span><br>DEERFIELD IL 60015 USA</p>
<p>MADE IN USA</p>
<p>DISTRIBUTED IN CANADA BY <br><span class="Bold">BAXTER CORPORATION</span><br>TORONTO ONTARIO CANADA</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>POTASSIUM CHLORIDE IN DEXTROSE 		
					</strong><br><span class="contentTableReg">potassium chloride and dextrose monohydrate injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0338-0683</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>POTASSIUM CHLORIDE</strong> (POTASSIUM CATION and CHLORIDE ION) </td>
<td class="formItem">POTASSIUM CHLORIDE</td>
<td class="formItem">150 mg  in 100 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>DEXTROSE MONOHYDRATE</strong> (ANHYDROUS DEXTROSE) </td>
<td class="formItem">DEXTROSE MONOHYDRATE</td>
<td class="formItem">5 g  in 100 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0338-0683-04</td>
<td class="formItem">1000 mL in 1 BAG; Combination Product Type = C112160</td>
<td class="formItem">02/01/1979</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA017634</td>
<td class="formItem">02/01/1979</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Baxter Healthcare Corporation
							(005083209)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Baxter Healthcare Corporation</td>
<td class="formItem"></td>
<td class="formItem">059140764</td>
<td class="formItem">MANUFACTURE(0338-0683), ANALYSIS(0338-0683), LABEL(0338-0683), PACK(0338-0683), STERILIZE(0338-0683)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Baxter Healthcare Corporation</td>
<td class="formItem"></td>
<td class="formItem">194684502</td>
<td class="formItem">ANALYSIS(0338-0683)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 3/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>dd7ba6f2-ee6f-4486-9d0e-21fb0b5e499f</div>
<div>Set id: 45de5402-5e61-4bbd-8bbc-5e3392c9920e</div>
<div>Version: 7</div>
<div>Effective Time: 20150307</div>
</div>
</div> <div class="DistributorName">Baxter Healthcare Corporation</div></p>
</body></html>
